Jefferies Financial Group Inc. Makes New $4.60 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM

Jefferies Financial Group Inc. bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 2nd quarter, Holdings Channel.com reports. The fund bought 39,260 shares of the company’s stock, valued at approximately $4,596,000.

Several other large investors have also made changes to their positions in the company. Nan Fung Trinity HK Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 45.6% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after acquiring an additional 71,214 shares in the last quarter. BlackRock Inc. bought a new stake in Mirum Pharmaceuticals in the second quarter worth $513,945,000. Emerald Advisers LLC raised its stake in Mirum Pharmaceuticals by 8.2% during the first quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock valued at $36,699,000 after purchasing an additional 30,129 shares in the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at $1,283,000. Finally, Rice Hall James & Associates LLC purchased a new position in Mirum Pharmaceuticals in the second quarter worth about $12,956,000.

Mirum Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ MIRM opened at $97.46 on Friday. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of -6.70 and a beta of 0.52. The company’s 50-day simple moving average is $110.63 and its 200-day simple moving average is $101.79. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.12) earnings per share. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president directly owned 1,274 shares of the company’s stock, valued at $127,400. The trade was a 96.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 133,156 shares of company stock valued at $13,763,562 over the last quarter. 8.32% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MIRM. Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. TD Cowen lowered their target price on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Wall Street Zen raised Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Wolfe Research started coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target for the company. Finally, CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $137.31.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.